Esparza-Salazar Felipe de Jesús, Lezama-Toledo Alma Rosa, Rivera-Monroy Germán, Borlongan Cesario V
Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Brain Circ. 2021 Mar 30;7(1):41-43. doi: 10.4103/bc.bc_21_21. eCollection 2021 Jan-Mar.
This review article discusses the preclinical evidence and clinical trials testing the use of a peptide agonist of the glucagon-like peptide (GLP) receptor that promotes insulin secretion in the animal models of and patient with Parkinson's disease (PD). In particular, we focus on the therapeutic effects of the GLP receptor agonist exendin-4, also called exenatide, in PD. The ultimate goal of this article is to provide a critical assessment of the laboratory and clinical data toward guiding the translation of exendin-4 as a clinically relevant therapeutic for PD.
这篇综述文章讨论了在帕金森病（PD）动物模型和患者中测试使用胰高血糖素样肽（GLP）受体肽激动剂促进胰岛素分泌的临床前证据和临床试验。特别是，我们重点关注GLP受体激动剂艾塞那肽-4（也称为艾塞那肽）在帕金森病中的治疗效果。本文的最终目标是对实验室和临床数据进行批判性评估，以指导将艾塞那肽-4转化为帕金森病的临床相关治疗方法。
